Algorae Pharmaceuticals Ltd (1AI) - Net Assets

Latest as of December 2025: AU$1.89 Million AUD ≈ $1.34 Million USD

Based on the latest financial reports, Algorae Pharmaceuticals Ltd (1AI) has net assets worth AU$1.89 Million AUD (≈ $1.34 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (AU$2.00 Million ≈ $1.42 Million USD) and total liabilities (AU$111.25K ≈ $78.72K USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check 1AI cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.

Key Net Assets Metrics

Metric Value
Current Net Assets AU$1.89 Million
% of Total Assets 94.44%
Annual Growth Rate N/A
5-Year Change 61.85%
10-Year Change -60.74%
Growth Volatility 167.4

Algorae Pharmaceuticals Ltd - Net Assets Trend (2004–2025)

This chart illustrates how Algorae Pharmaceuticals Ltd's net assets have evolved over time, based on quarterly financial data. Also explore Algorae Pharmaceuticals Ltd assets under control for the complete picture of this company's asset base.

Annual Net Assets for Algorae Pharmaceuticals Ltd (2004–2025)

The table below shows the annual net assets of Algorae Pharmaceuticals Ltd from 2004 to 2025. For live valuation and market cap data, see Algorae Pharmaceuticals Ltd (1AI) total market value.

Year Net Assets Change
2025-06-30 AU$2.23 Million
≈ $1.58 Million		 -58.06%
2024-06-30 AU$5.31 Million
≈ $3.76 Million		 -8.13%
2023-06-30 AU$5.78 Million
≈ $4.09 Million		 +43.37%
2022-06-30 AU$4.03 Million
≈ $2.85 Million		 +192.99%
2021-06-30 AU$1.38 Million
≈ $974.40K		 -52.16%
2020-06-30 AU$2.88 Million
≈ $2.04 Million		 -30.45%
2019-06-30 AU$4.14 Million
≈ $2.93 Million		 -42.00%
2018-06-30 AU$7.14 Million
≈ $5.05 Million		 -5.09%
2017-06-30 AU$7.52 Million
≈ $5.32 Million		 +32.44%
2016-06-30 AU$5.68 Million
≈ $4.02 Million		 +10.72%
2015-06-30 AU$5.13 Million
≈ $3.63 Million		 -39.19%
2014-06-30 AU$8.43 Million
≈ $5.97 Million		 -36.38%
2013-06-30 AU$13.25 Million
≈ $9.38 Million		 -7.67%
2012-06-30 AU$14.35 Million
≈ $10.16 Million		 +112.32%
2011-06-30 AU$6.76 Million
≈ $4.78 Million		 +8.34%
2010-06-30 AU$6.24 Million
≈ $4.41 Million		 +12.89%
2009-06-30 AU$5.53 Million
≈ $3.91 Million		 -51.87%
2008-06-30 AU$11.48 Million
≈ $8.13 Million		 +719.49%
2007-06-30 AU$1.40 Million
≈ $991.53K		 -21.98%
2006-06-30 AU$1.80 Million
≈ $1.27 Million		 -42.72%
2005-06-30 AU$3.14 Million
≈ $2.22 Million		 +336.57%
2004-06-30 AU$-1.33 Million
≈ $-937.82K		 --

Equity Component Analysis

This analysis shows how different components contribute to Algorae Pharmaceuticals Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have decreased by 6957756500.0% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (June 2025)

Component Amount Percentage
Common Stock AU$81.54 Million 3658.51%
Other Comprehensive Income AU$573.33K 25.72%
Total Equity AU$2.23 Million 100.00%

Algorae Pharmaceuticals Ltd Competitors by Market Cap

The table below lists competitors of Algorae Pharmaceuticals Ltd ranked by their market capitalization.

Company Market Cap
Digicontent Limited
NSE:DGCONTENT
 $20.05 Million
Tower Resources Ltd
V:TWR
 $20.06 Million
E-Home Household Service Holdings Ltd
NASDAQ:EJH
 $20.07 Million
Rocketdna Ltd
AU:RKT
 $20.09 Million
Aarvi Encon Limited
NSE:AARVI
 $20.04 Million
Energoaparatura S.A.
WAR:ENP
 $20.04 Million
Hifab Group AB Series B
ST:HIFA-B
 $20.03 Million
Euroconsultants SA
AT:EUROC
 $20.03 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Algorae Pharmaceuticals Ltd's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2024 to 2025, total equity changed from 3,014,250 to 2,228,796, a change of -785,454 (-26.1%).
  • Net loss of 802,958 reduced equity.
  • Other comprehensive income increased equity by 16,254.

Equity Change Factors (2024 to 2025)

Factor Impact Contribution
Net Income AU$-802.96K -36.03%
Other Comprehensive Income AU$16.25K +0.73%
Other Changes AU$1.25K +0.06%
Total Change AU$- -26.06%

Book Value vs Market Value Analysis

This analysis compares Algorae Pharmaceuticals Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 10.60x
  • The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
2004-06-30 AU$-0.07 AU$0.01 x
2005-06-30 AU$0.04 AU$0.01 x
2006-06-30 AU$0.02 AU$0.01 x
2007-06-30 AU$0.01 AU$0.01 x
2008-06-30 AU$0.06 AU$0.01 x
2009-06-30 AU$0.02 AU$0.01 x
2010-06-30 AU$0.02 AU$0.01 x
2011-06-30 AU$0.02 AU$0.01 x
2012-06-30 AU$0.04 AU$0.01 x
2013-06-30 AU$0.04 AU$0.01 x
2014-06-30 AU$0.02 AU$0.01 x
2015-06-30 AU$0.01 AU$0.01 x
2016-06-30 AU$0.01 AU$0.01 x
2017-06-30 AU$0.01 AU$0.01 x
2018-06-30 AU$0.01 AU$0.01 x
2019-06-30 AU$0.01 AU$0.01 x
2020-06-30 AU$0.00 AU$0.01 x
2021-06-30 AU$0.00 AU$0.01 x
2022-06-30 AU$0.00 AU$0.01 x
2023-06-30 AU$0.00 AU$0.01 x
2024-06-30 AU$0.00 AU$0.01 x
2025-06-30 AU$0.00 AU$0.01 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Algorae Pharmaceuticals Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): -36.03%
  • The company may be facing challenges in efficiently utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: -569.27%
  • • Asset Turnover: 0.06x
  • • Equity Multiplier: 1.08x
  • Recent ROE (-36.03%) is above the historical average (-95.49%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2006 -379.70% -521775.90% 0.00x 2.37x AU$-7.00 Million
2007 -427.26% -32877.50% 0.00x 2.72x AU$-6.13 Million
2008 -59.16% -20828.47% 0.00x 1.06x AU$-7.94 Million
2009 -110.79% -3294.97% 0.03x 1.18x AU$-6.68 Million
2010 -90.94% -1885.46% 0.04x 1.11x AU$-6.30 Million
2011 -100.52% -3849.43% 0.02x 1.11x AU$-7.47 Million
2012 39.55% 153.07% 0.24x 1.08x AU$4.24 Million
2013 -22.48% -39.30% 0.53x 1.07x AU$-4.30 Million
2014 -80.40% -91.68% 0.77x 1.15x AU$-7.62 Million
2015 -137.38% -1150.97% 0.11x 1.07x AU$-7.56 Million
2016 -54.49% -2575.68% 0.02x 1.11x AU$-3.66 Million
2017 -54.40% -3548.14% 0.01x 1.16x AU$-4.84 Million
2018 -5.25% -4113.04% 0.00x 1.07x AU$-1.09 Million
2019 -76.87% -32565.90% 0.00x 1.39x AU$-3.60 Million
2020 -33.65% -30570.36% 0.00x 1.18x AU$-1.26 Million
2021 -106.06% -544.63% 0.16x 1.19x AU$-1.60 Million
2022 -48.51% -57398.83% 0.00x 1.06x AU$-2.36 Million
2023 -56.02% -5015.84% 0.01x 1.66x AU$-2.48 Million
2024 -69.52% -1673.77% 0.02x 1.82x AU$-2.40 Million
2025 -36.03% -569.27% 0.06x 1.08x AU$-1.03 Million

Industry Comparison

This section compares Algorae Pharmaceuticals Ltd's net assets metrics with peer companies in the Biotechnology industry.

Industry Context

  • Industry: Biotechnology
  • Average net assets among peers: $14,887,998
  • Average return on equity (ROE) among peers: -57.94%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Algorae Pharmaceuticals Ltd (1AI) AU$1.89 Million -379.70% 0.06x $20.04 Million
Adalta Ltd (1AD) $5.38 Million -112.69% 0.98x $8.12 Million
ACRUX Ltd (ACR) $43.92 Million -0.55% 0.08x $3.49 Million
Actinogen Medical Ltd (ACW) $15.66 Million -63.12% 0.04x $103.45 Million
Argenica Therapeutics Ltd (AGN) $13.95 Million -39.28% 0.17x $15.45 Million
Arovella Therapeutics Ltd (ALA) $8.35 Million -58.19% 0.43x $66.62 Million
Anatara Lifesciences Ltd (ANR) $3.83 Million -52.11% 0.13x $1.57 Million
Alterity Therapeutics Ltd (ATH) $30.47 Million -50.24% 0.10x $80.80 Million
Amplia Therapeutics Ltd (ATX) $9.77 Million -46.00% 0.04x $54.45 Million
Avecho Biotechnology Ltd (AVE) $2.65 Million -99.27% 0.26x $31.19 Million

About Algorae Pharmaceuticals Ltd

AU:1AI Australia Biotechnology
Market Cap
$20.04 Million
AU$28.32 Million AUD
Market Cap Rank
#25025 Global
#1098 in Australia
Share Price
AU$0.01
Change (1 day)
+7.69%
52-Week Range
AU$0.01 - AU$0.02
All Time High
AU$0.25
Categories
Companies in Australia Biotechnology
About

Algorae Pharmaceuticals Limited, a pharmaceutical development company, engages in the research and development of living cells technologies primarily in New Zealand. The company's product pipeline includes AI-116, a novel combination drug candidate made up of donepezil and cannabidiol for the treatment of dementia, including Alzheimer's disease; AI-168, a novel combination drug candidate made up … Read more